BP-294 (Ste Civile Bioprojet).
作者信息
Fozard J R
机构信息
Research Department, Novartis Pharma AG, Building 386/1035, Postfach, CH-4002 Basel, Switzerland.
出版信息
IDrugs. 2000 Aug;3(8):935-9.
PMID:16059810
Abstract
BP-294 (a prodrug of R-alpha-methylhistamine) is a histamine-H(3) agonist under development by Bioprojet, which is currently in phase II clinical trials as a potential treatment for asthma [219798].
摘要
Zotero 插件